Published in Breast Cancer Res on January 26, 2005
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci U S A (2006) 1.61
Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol (2011) 1.31
Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res (2012) 1.13
Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Res (2011) 1.06
The important molecular markers on chromosome 17 and their clinical impact in breast cancer. Int J Mol Sci (2011) 0.93
MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC). Oncotarget (2015) 0.84
Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer. BMC Clin Pathol (2006) 0.83
Her-2 immunohistochemical expression in oral squamous cell carcinomas is associated with polysomy of chromosome 17, not Her-2 amplification. Head Neck Pathol (2009) 0.80
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients. Breast Cancer Res Treat (2016) 0.79
Involvement of HER-2/neu and metastasis-related proteins in the development of ileal neuroendocrine tumors. Virchows Arch (2011) 0.79
Impact of polysomy 17 on HER2 testing of invasive breast cancer patients. Int J Clin Exp Pathol (2013) 0.76
ROS1 copy number alterations are frequent in non-small cell lung cancer. Oncotarget (2016) 0.75
Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancer. Oncologist (2012) 0.75
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification. Am J Cancer Res (2015) 0.75
Cytogenetic significance of chromosome 17 aberrations and P53 gene mutations as prognostic markers in oral squamous cell carcinoma. Diagn Pathol (2015) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol (1999) 11.78
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (1985) 9.12
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol (1996) 4.99
The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science (1986) 3.74
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res (1998) 3.39
Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene (1996) 3.33
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A (1992) 3.25
The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett (1997) 3.23
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol (1992) 3.17
Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res (1994) 3.03
neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol (1998) 2.42
Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene (1998) 1.98
Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res (1993) 1.82
Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol (2001) 1.76
HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc (2002) 1.59
HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells (1997) 1.49
Gene amplification and tumor progression. Biochim Biophys Acta (1993) 1.46
Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics (1989) 1.43
Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat (2003) 1.30
Chromosome analysis of 97 primary breast carcinomas: identification of eight karyotypic subgroups. Genes Chromosomes Cancer (1995) 1.15
Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn (2003) 1.12
Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol (2002) 1.05
Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol (2004) 1.04
Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy. Breast J (2002) 1.01
HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol (2002) 0.99
EGF-related peptides and their receptors in mammary gland development. J Mammary Gland Biol Neoplasia (1997) 0.90
Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin Oncol (2000) 0.86
Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization. Cancer (2001) 0.85
EGF-related peptides in the pathophysiology of the mammary gland. J Mammary Gland Biol Neoplasia (1997) 0.83
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol (2009) 4.12
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol (2012) 3.88
B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat Immunol (2011) 3.66
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med (2012) 3.44
Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica (2005) 3.24
Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation. Genes Chromosomes Cancer (2004) 2.22
Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res (2010) 2.00
Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood (2011) 1.98
Host cell-derived cardiomyocytes in sex-mismatch cardiac allografts. Cardiovasc Res (2002) 1.76
Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. J Invest Dermatol (2009) 1.65
Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica (2010) 1.60
A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res (2008) 1.55
Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol (2005) 1.44
Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon. Haematologica (2002) 1.42
Bendamustine-containing immunochemotherapy is active in transformed follicular lymphoma with overexpression of p53. Leuk Lymphoma (2009) 1.42
MYC copy number gains are associated with poor outcome in penile squamous cell carcinoma. J Urol (2012) 1.42
Fluorescence in situ hybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia. Leuk Lymphoma (2014) 1.39
[Persistent polyclonal B-cell lymphocytosis: study of 35 cases]. Med Clin (Barc) (2011) 1.38
Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2005) 1.23
In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica (2011) 1.22
MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica (2013) 1.19
MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas. Cancer Res (2009) 1.15
Primary bone marrow lymphoma: an uncommon extranodal presentation of aggressive non-hodgkin lymphomas. Am J Surg Pathol (2012) 1.15
Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res (2012) 1.13
KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations. Mod Pathol (2008) 1.12
Identification of male cardiomyocytes of extracardiac origin in the hearts of women with male progeny: male fetal cell microchimerism of the heart. J Heart Lung Transplant (2005) 1.11
Nitric oxide synthases and protein oxidation in the quadriceps femoris of patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol (2003) 1.10
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol (2013) 1.10
Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol (2006) 1.09
Vulvar angiomyxoma, aggressive angiomyxoma, and angiomyofibroblastoma: an immunohistochemical and ultrastructural study. Ultrastruct Pathol (2006) 1.05
CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. Int J Cancer (2013) 1.05
TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms. Ann Hematol (2011) 1.03
Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis. PLoS One (2011) 1.03
Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results. Br J Haematol (2012) 1.03
Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys (2006) 1.02
Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. Clin Cancer Res (2009) 1.02
Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. Cancer (2011) 1.00
Intraosseous intraneural perineurioma: report of a case with morphological, immunohistochemical and FISH study. Med Oral (2004) 0.99
Epidermal growth factor receptor gene numerical aberrations are frequent events in actinic keratoses and invasive cutaneous squamous cell carcinomas. Exp Dermatol (2010) 0.99
Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat (2010) 0.98
The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma. Cancer Genet Cytogenet (2006) 0.98
Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer (2010) 0.98
Clonal proliferation of cyclin D1-positive mantle lymphocytes in an asymptomatic patient: an early-stage event in the development or an indolent form of a mantle cell lymphoma? Hum Pathol (2005) 0.98
Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. J Clin Oncol (2013) 0.97
Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. Haematologica (2008) 0.96
Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol (2008) 0.94
Acute erythroid neoplastic proliferations. A biological study based on 62 patients. Haematologica (2002) 0.94
Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients. Br J Haematol (2011) 0.94
Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. Br J Haematol (2009) 0.93
Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood (2003) 0.92
HPV testing by cobas HPV test in a population from Catalonia. PLoS One (2013) 0.92
FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors. Breast Cancer Res (2009) 0.92
Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer. Cancer Treat Rev (2008) 0.92
Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol (2002) 0.92
Genetic diagnosis by comparative genomic hybridization in adult de novo acute myelocytic leukemia. Cancer Genet Cytogenet (2004) 0.92
Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 1. Synchronous mucosa-associated lymphoid tissue lymphoma and gastrointestinal stromal tumors of the stomach. J Clin Oncol (2005) 0.91
Identification of temporal and region-specific myocardial gene expression patterns in response to infarction in swine. PLoS One (2013) 0.91
Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques. Genes Chromosomes Cancer (2008) 0.91
Study of regulatory T-cells in patients with gastric malt lymphoma: influence on treatment response and outcome. PLoS One (2012) 0.90
Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer. Breast (2011) 0.90
Human papillomavirus detection in urine samples: an alternative screening method. J Low Genit Tract Dis (2007) 0.90
Factors affecting 5- and 10-year survival of women with breast cancer: an analysis based on a public general hospital in Barcelona. Cancer Epidemiol (2012) 0.89
3q26 (hTERC) gain studied by fluorescence in situ hybridization as a persistence-progression indicator in low-grade squamous intraepithelial lesion cases. Hum Pathol (2009) 0.89
Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome. Am J Hematol (2007) 0.88